Brought to you by 
Corcept licenses technology from Stanford
30 Mar 2005
Executive Summary
Exercising its rights under an option agreement signed in 1998, Corcept Therapeutics (psychiatric drugs) licensed from Stanford University exclusive rights to glucocorticoid receptor antagonist patents for treating psychotic major depression and early dementia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Corcept licenses technology from Stanford
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice